Endonovo Therapeutics, Inc. (ENDV) insider have most recently took part in a trading activity. On Nov 24, 2017 Mann Michael Scott, President, 10% Owner bought 21,000 shares having total worth of $1,260 at the price of $0.06 per share, following the transaction a total of 24,273,189 shares owned by Mann Michael Scott. Before this latest buy, Mann Michael Scott purchased ENDV at 130 other times during the past twelve months, for a total investment of $21.28M at an average of $0.09 per share.
The stock has experienced a total of 23 insider trades in the past three months. These trades include 23 buy trades. Furthermore, over the past 12 months , the stock was traded 130 times by insiders. an employee of the company was the buyer in 130 instances.
|Time Frame||Number of Insider Buy||Number of Insider Sell||Stock Price Change(%)|
Hanover Portfolio Acquisitions Inc is comprised of two business segments: a debt portfolio management company and an intellectual property management and commercialization company. Debt portfolio management segment purchases defaulted, unsecured, consumer receivables in the secondary market and generates revenue through collections utilizing an outsourced collection network and through the strategic resale of portfolios. This segment acquires credit-card receivable portfolios at significant discounts to the total amounts owed by the debtors. Intellectual property management and commercialization segment is operated through the company’s wholly-owned subsidiary, IP Resources International, Inc. (IPR). IPR focuses on licensing various commercially desirable technologies and patents from companies that need operating capital or that need help commercializing their technology and sublicense such technology in designated territories.
Latest posts by William White (see all)
- Insider Trading Review: FS Investment Corporation $FSIC - January 13, 2018
- Insider Trader Watch: ENERTOPIA CORP $ENRT - January 13, 2018
- Insider Trading in Focus: Swiss Helvetia Fund, Inc. (The) $SWZ - January 13, 2018